Taysha Gene Therapies Inc (TSHA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.32B
Last updated: Nov 17, 2026 at 4:11 PM ET
Taysha Gene Therapies Inc (TSHA) Statistics
Taysha Gene Therapies (TSHA) has a market cap of $1.32B and an enterprise value of $948.24M. It kept -2844.63% of revenue as net income over the last 12 months. Its share count is up 14.94% from a year earlier.
Total Valuation
Enterprise value is 28.37% below the market cap, as cash exceeds debt.
| Market Cap | $1.32B |
|---|---|
| Enterprise Value | $948.24M |
| Latest price (Nov 17, 2026) | $4.00 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 296.2x and 4.6x. Its year-end P/S ranged from 10.5x to 169.9x from 2022 to 2025.
| P/S Ratio | 296.2x |
|---|---|
| P/B Ratio | 4.6x |
Price Statistics
The stock is down 3.15% over 52 weeks and trades 9.71% below its 50-day average.
| Beta (1Y) | 1.69 |
|---|---|
| 52-Week Change | -3.15% |
| 1-Month Change | +1.52% |
| 3-Month Change | -37.79% |
| 6-Month Change | -22.85% |
| 5-Year Change | -73.59% |
| Total Return (1Y) | -3.15% |
| Total Return (3Y CAGR) | +33.00% |
| Total Return (5Y CAGR) | -21.95% |
| Return vs SPY (1Y) | -15.17% |
| Max Drawdown (1Y) | -49.71% |
| Max Drawdown (3Y) | -72.90% |
| Sharpe Ratio (1Y) | -0.05 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $4.43 |
| 200-Day Average | $5.29 |
| 52-Week Range | $3.46 to $7.30 |
| RSI (14 Days) | 41.9 |
| Average Volume (20 Days) | 2.89M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 18.56x current liabilities, and total debt is 0.13x shareholder equity.
| Current Ratio | 18.56x |
|---|---|
| Quick Ratio | 18.56x |
| Debt / Equity | 0.13x |
| Interest Coverage | -5409.06x |
Returns and Efficiency
Return on invested capital is -32.76% over the last 12 months, against a 5-year average of -31.42%.
| Return on Equity (ROE) | -43.71% |
|---|---|
| Return on Assets (ROA) | -35.87% |
| Return on Invested Capital (ROIC) | -32.76% |
| ROA (5Y Average) | -73.01% |
| ROIC (5Y Average) | -31.42% |
| Asset Turnover | 0.01x |
Scores
TSHA has an Altman Z-Score of 9.64, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 9.64 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $5.49M over the last 12 months is down 13.07% from the 12 months before.
| Revenue | $5.49M |
|---|---|
| Revenue Growth (YoY) | -13.07% |
| Gross Profit | $5.49M |
| Operating Income | -$161.01M |
| Pretax Income | -$156.03M |
| Net Income | -$156.03M |
| Reported EPS (TTM) | -$0.41 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 82.06% of the $435.03M in total assets.
| Cash and Equivalents | $422.83M |
|---|---|
| Total Debt | $47.33M |
| Net Cash | $375.50M |
| Net Cash Per Share | $0.92 |
| Working Capital | $403.11M |
| Shareholder Equity | $356.97M |
| Book Value Per Share | $0.88 |
| Total Assets | $435.03M |
| Total Liabilities | $78.06M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $718.00K of capital spending, operating cash flow left -$141.66M of free cash flow.
| Operating Cash Flow | -$140.94M |
|---|---|
| Capital Expenditures | $718.00K |
| Free Cash Flow | -$141.66M |
| FCF Per Share | -$0.43 |
| Depreciation and Amortization | $1.14M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2935.41%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -2935.41% |
| Pretax Margin | -2844.63% |
| Net Margin | -2844.63% |
| FCF Margin | -2582.63% |
Growth
Revenue grew 57.49% a year over 3 years.
| Revenue Growth (3Y CAGR) | +57.49% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | +38.82% |
| Tangible Book Per Share Growth (2Y CAGR) | +38.82% |
Dividends and Yields
TSHA does not pay a dividend. Its free cash flow yield is -8.72%.
| FCF Yield | -8.72% |
|---|---|
| Buyback Yield | -16.30% |
| Shareholder Yield | -16.30% |
Peer Position
Against 8 similar companies, TSHA has the 2nd highest P/S.
P/S RatioPeer median 12.3x
ROICPeer median -38.09%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +35.11%
| P/S Ratio | 296.2x vs 12.3x median |
|---|---|
| ROIC | -32.76% vs -38.09% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -13.07% vs +35.11% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.07% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.07% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TSHA
What is TSHA's market cap?
Taysha Gene Therapies has a market cap of $1.32B. Its enterprise value, which adds debt and subtracts cash, is $948.24M.
How many shares of TSHA are outstanding?
Taysha Gene Therapies has 406.11M shares outstanding. The count is up 14.94% from a year earlier.
Does TSHA pay a dividend?
No. Taysha Gene Therapies does not pay a dividend.
How much debt does TSHA have?
Taysha Gene Therapies has $47.33M of total debt and $422.83M of cash and equivalents, a net cash position of $375.50M.
TSHA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors